GlassScriptPhysician profile
Rachael Ann Gilbert
NPI 1427680974
$8,101.42
in general payments reported to CMS, 2019-2025
56 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $146 · 2023: $2,330 · 2024: $2,349 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,091 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,090.67 |
| Education | $343.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $799.17 | 2021-2025 | Darzalex, Imbruvica, Tecvayli |
| Merck Sharp & Dohme LLC | $682.74 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $546.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $500.26 | 2021-2025 | Tagrisso, Enhertu, Calquence |
| Regeneron Healthcare Solutions, INC. | $354.70 | 2023-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $349.89 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $333.94 | 2023-2025 | |
| Seagen INC. | $326.33 | 2021-2025 | Padcev, Tukysa |
| Incyte Corporation | $260.58 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $257.00 | 2023-2025 | Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $252.94 | 2021-2025 | |
| Celgene Corporation | $197.69 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Genmab U.S., INC. | $176.03 | 2023-2025 | Tivdak, Epkinly |
| Genentech USA, INC. | $173.22 | 2023-2025 | Tecentriq, Polivy, Lunsumio |
| Takeda Pharmaceuticals U.S.A., INC. | $161.92 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $149.11 | 2023-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $145.38 | 2021-2025 | Xpovio |
| Cumberland Pharmaceuticals, INC. | $138.23 | 2023-2024 | Sancuso |
| Genzyme Corporation | $134.80 | 2022-2025 | |
| Coherus Oncology, INC. | $132.40 | 2023-2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $131.23 | 2021-2025 | Monoferric |
| Emd Serono, INC. | $130.13 | 2023-2025 | Bavencio |
| Eisai INC. | $124.83 | 2021-2025 | |
| Amgen INC. | $116.53 | 2021 | |
| Pfizer INC. | $106.49 | 2023-2025 | |
| Lilly USA, LLC | $100.90 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $98.42 | 2025 | Vyloy |
| Glaxosmithkline, LLC. | $90.54 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $88.98 | 2023-2025 | |
| Blueprint Medicines Corporation | $84.17 | 2023-2025 | Ayvakit |
| Stemline Therapeutics INC. | $79.28 | 2023-2024 | Orserdu, Elzonris |
| Pharmaessentia USA Corporation | $77.70 | 2023-2025 | Besremi |
| Puma Biotechnology, INC. | $57.79 | 2021-2025 | |
| Beone Medicines USA, INC. | $56.30 | 2025 | Tevimbra, Brukinsa |
| Progenics Pharmaceuticals, INC. | $51.86 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.36 | 2021-2023 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $45.23 | 2023 | Yonsa, Odomzo |
| Morphosys, US INC. | $45.17 | 2022-2023 | Monjuvi |
| Sobi, INC | $42.28 | 2024 | |
| Array Biopharma INC | $40.31 | 2021-2025 | Mektovi, Braftovi, Tukysa |
| Kyowa Kirin, INC. | $37.41 | 2021-2025 | |
| Adc Therapeutics America, INC. | $36.96 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $35.65 | 2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $35.49 | 2025 | |
| Beigene USA, INC. | $35.04 | 2024 | Brukinsa |
| Caris Mpi, INC. | $32.66 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $29.79 | 2023 | Somatuline Depot, Onivyde, Tazverik |
| Celltrion USA INC. | $24.47 | 2025 | Vegzelma |
| Iovance Biotherapeutics, INC. | $21.02 | 2025 | Amtagvi |
| Gilead Sciences, INC. | $20.50 | 2025 | Trodelvy |
| Agios Pharmaceuticals, INC. | $20.42 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $18.82 | 2023 | Rolvedon |
| Novo Nordisk INC | $17.94 | 2023 | Rybelsus, Ozempic |
| G1 Therapeutics, INC. | $17.85 | 2023 | Cosela |
| Tersera Therapeutics LLC | $13.72 | 2025 | Zoladex |
| Springworks Therapeutics, INC. | $13.54 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.